Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Are you interested in Orthogonal Bioinformatic Validation? Join us online for a presentation by Tim Hague for a comprehensive introduction to Omixon’s Holotype HLA Genotyping Assay and HLA Twin™ Genotyping Software. The presentation will have a training/workshop format, including …more
When carrying out clinical trials, one of the most important logistical and statistical challenges is ensuring that your data accurately reflects the population you are setting out to study. None of us has the resources to test a drug on …more